Sanyou Bio Launches Innovation Hub After Decade Building Super-Trillion Antibody Library

Ten years ago, Lang Guojun left his job at a pharmaceutical company and saw a gap that no one else seemed to be filling. China's biotech industry was growing fast—companies were learning to manufacture drugs, run clinical trials, commercialize products—but at the very beginning of the chain, where new molecules are discovered, there was almost nothing. No platforms. No infrastructure. Just a void. In 2015, he founded Sanyou Biopharmaceuticals in Shanghai to fill it.

Today, Sanyou Bio is launching an Innovation Hub—a digital platform designed to connect the scattered pieces of drug discovery into one place. The company has grown from three people working in a 100-square-meter lab to more than 200 employees operating over 20,000 square meters of research and manufacturing facilities. The centerpiece of that growth is something called the Intelligent Super-Trillion Antibody Library, a collection of ten trillion molecular candidates that the company has spent a decade assembling. To put that in perspective: most competitors in China maintain libraries of 10 billion to 100 billion molecules. Sanyou's is 100 to 1,000 times larger.

Why does size matter? Because when a researcher is hunting for a molecule that can bind to a specific disease target, a bigger library means more options. A library of 100 billion might yield dozens of promising candidates. A library of 10 trillion can theoretically produce tens of thousands. That abundance changes the math downstream. It means higher success rates in the early stages of drug development, which means fewer failed projects, which means faster paths to the clinic. Lang describes it plainly: "For any target, we can provide a rich pool of high-quality candidates, significantly increasing downstream R&D success rates from the very beginning."

Building that library was not the only thing Sanyou had to do to survive. The company also had to make money. Many biotech startups live on venture capital until it runs out, then they disappear. Sanyou pursued what Lang calls a dual-engine strategy: R&D innovation on one side, commercial operations on the other. The company took on contract work—over the past decade, it completed more than 2,000 projects for more than 2,000 clients. That steady revenue stream kept the lights on. In 2024, Sanyou reached break-even. In 2025, it turned a profit and maintained positive cash flow. That financial stability is rare in biotech, and it matters because it means the company can think beyond the next funding round.

The Innovation Hub is the result of that thinking. It consolidates more than 70 different service platforms and tools into a single digital interface. A researcher or a biotech company can log in and access antibody screening, antibody engineering, animal models, cell line development, formulation work, quality control—the entire chain from discovery through preclinical research. The platform also includes a marketplace connecting clients with contract manufacturers and other service providers. The goal is to reduce friction. Instead of managing relationships with a dozen different vendors, a client can work through one portal.

But the platform is designed to do more than just organize services. Lang envisions it as a hub that connects three worlds that usually operate separately: academic laboratories with promising early-stage discoveries but no path to development; pharmaceutical companies with capital and expertise but limited bandwidth to evaluate every early project; and investors looking for high-quality opportunities but drowning in due diligence. Sanyou positions itself as the trusted intermediary. It can introduce an academic lab to a CDMO, or help a U.S. biotech company navigate China's regulatory landscape and find local partners. It can help investors screen projects and provide technical support after they invest. In each case, Sanyou is not just providing a service—it is vouching for the quality of the match.

Lang is careful about the future. He notes that 95 percent of companies do not survive beyond ten years. He has no interest in grand ten-year plans. "Rather than thinking about what things will look like in 15 or 20 years, our priority is to make 2026 the best version it can be." The Innovation Hub is his answer to that question. It is a platform built on a decade of accumulated relationships, data, and technical capability. As it grows, it will accumulate more data—information about which molecules work, which development strategies succeed, which partnerships produce results. That data, fed into artificial intelligence models, becomes a competitive advantage that is hard to replicate. The platform's long-term value lies not in the services it offers today, but in the network effects and proprietary insights it will generate tomorrow.